Latest California Healthline Stories
KFF Health News' 'What the Health?': Health Funding in Question in a Speaker-Less Congress
A bitterly divided Congress managed to keep the federal government running for several more weeks, while House Republicans struggle — again — to choose a leader. Meanwhile, many people removed from state Medicaid rolls are not finding their way to Affordable Care Act insurance, and a major investigation by The Washington Post attributes the decline in U.S. life expectancy to more than covid-19 and opioids. Lauren Weber of The Washington Post, Victoria Knight of Axios, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews physician-author-playwright Samuel Shem about “Our Hospital,” his new novel about the health workforce in the age of covid.
An Arm and a Leg: John Green vs. Johnson & Johnson (Part 1)
Pharmaceutical patents can drive up the costs of lifesaving medications. Hear what author and YouTube star John Green is doing to make tuberculosis drugs more accessible to the people who need them most.
Trump Misplaced Blame When He Said Drug Shortages Were Biden’s Fault
Former President Donald Trump, who’s running for another term in the White House, recently blamed drug shortages on his successor, President Joe Biden. Our findings don’t align with Trump’s claims; by some measures, drug shortages increased more on Trump’s watch than on Biden’s.
Florida Foster Kids Are Given Powerful Medications, but Feds Find State Oversight Lacking
A report by the U.S. Department of Health and Human Services raises troubling questions about the use of powerful medications within Florida’s child welfare system and the risk of overdoses or dangerous side effects if children are given the wrong combination of drugs.
KFF Health News' 'What the Health?': Countdown to Shutdown
Congress appears to be careening toward a government shutdown, as a small band of House conservatives vow to block any funding for the fiscal year that begins Oct. 1 unless they win deeper cuts to health and other domestic programs. Meanwhile, former President Donald Trump continues to roil the GOP presidential primary field, this time with comments about abortion. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Tami Luhby of CNN join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
Humira lleva 20 años disfrutando de una exclusividad muy cara en el país. Sus competidores podrían ahorrarle al sistema sanitario $9,000 millones.
Por qué los CDC recomiendan el nuevo refuerzo contra covid para todos
El Comité Asesor sobre Prácticas de Inmunización de los CDC votó 13-1 a favor de la moción después de meses de debate sobre si limitar los refuerzos a grupos de alto riesgo.
Why the CDC Has Recommended New Covid Boosters for All
As covid-19 hospitalizations tick upward with fall approaching, the CDC says it’s time for new boosters — and not only for those at highest risk of serious disease. Here are seven things you need to know.
KFF Health News' 'What the Health?': Welcome Back, Congress. Now Get to Work.
Congress returns from its summer recess with a long list of tasks and only a few work days to get them done. On top of the annual spending bills needed to keep the government operating, on the list are bills to renew the global HIV/AIDS program, PEPFAR, and the community health centers program. Meanwhile, over the recess, the Biden administration released the names of the first 10 drugs selected for the Medicare price negotiation program.